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Aim: To investigate the point prevalence of hereditary neuromuscular disorders on 
January	1,	2020	in	Northern	Norway.
Methods: From	January	1,	1999,	until	January	1,	2020,	we	screened	medical	and	ge-
netic hospital records in Northern Norway for hereditary neuromuscular disorders.
Results: We	 identified	542	patients	with	 a	hereditary	neuromuscular	 disorder	 liv-
ing	in	Northern	Norway,	giving	a	point	prevalence	of	111.9/100,000	on	January	1,	
2020. The prevalence of children (<18	years	 old)	 and	 adults	 (≥18	 years	 old)	were	
57.8/100,000	and	125.1/100,000,	respectively.	Inherited	neuropathies	had	a	prev-
alence	of	 38.8/100,000.	Charcot–Marie–Tooth	 and	hereditary	 neuropathy	with	 li-
ability	 to	 pressure	 palsies	 had	 a	 prevalence	 of	 29.9/100,000	 and	 8.3/100,000,	
respectively.	We	calculated	a	prevalence	of	3.7/100,000	 for	 spinal	muscular	 atro-






Conclusion: Our	 total	 prevalence	 was	 higher	 than	 previously	 hypothesized	 in	
European population-based studies. The prevalence was especially high for myotonia 
congenita	 and	 limb-girdle	muscular	 dystrophy.	 The	 prevalence	 of	 Charcot–Marie–
Tooth	 polyneuropathy	was	 higher	 than	 in	most	 European	 studies,	 but	 lower	 than	
previously reported in epidemiological studies in other regions of Norway.
K E Y W O R D S
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1  | INTRODUC TION
Hereditary neuromuscular disorders (HNMD) are a heterogeneous 
group	of	diseases	affecting	muscles,	neuromuscular	junctions,	motor	
neuron	cell	bodies	and	peripheral	nerves.	These	disorders	are	 rare,	
but collectively the influence on health care is noteworthy. Many pa-
tients with HNMD need extensive healthcare services. Due to the 
lack	of	knowledge	of	HNMD	among	healthcare	providers,	follow-up	






Apart	 from	 historical	 studies	 (Emery,	 1991;	 Hughes	 et	 al.,	 1996),	
the	 total	 prevalence	 of	 HNMD	 in	 Europe	 is	 speculative	 (Lefter	
et	 al.,	 2017;	 Norwood	 et	 al.,	 2009).	 Few	 Scandinavian	 studies	 on	
the	 prevalence	 of	 inherited	 neuromuscular	 disorders	 exist.	 A	 few	
comprise	exclusively	children	with	HNMD	(Darin	&	Tulinius,	2000;	
Rasmussen	 et	 al.,	 2012),	 while	 others	 are	 reports	 on	 specific	
HNMD	(Braathen	et	al.,	2011;	Lindberg	&	Bjerkne,	2017;	Papponen	
et	al.,	1999;	Stensland	et	al.,	2011;	Sveen	et	al.,	2006).	Although	a	




treatment and follow-up of HNMD patients. Epidemiological data 
are necessary to develop clinical management programs and prepare 
for clinical trials. The increasing molecular diagnostic possibilities 
and emerging treatment options make awareness of the prevalence 
even more important. The aim of this study is to estimate the point 
prevalence (PP) of HNMD and its subcategories in Northern Norway.
2  | METHODS
2.1 | Participants, study design and setting
We collected information from the electronic patient hospital re-
cords	(EPR)	of	Northern	Norway	(DIPS	ASA,	Bodø),	the	Norwegian	
registry	 of	 hereditary	 and	 congenital	 neuromuscular	 disorders,	
and	medical	 genetics	 records	 at	 the	University	 Hospital	 of	 North	
Norway	(UNN)	in	Tromsø.	All	regional	health	institutions	in	Northern	
Norway	 (UNN,	 Finnmark	 Hospital	 Trust,	 Nordland	 Hospital	 Trust	




Specified	 ICD-10	 diagnoses	 that	 were	 reviewed	 for	 HNMD	 in	
this	study	are	listed	in	Table	1.	In	order	to	identify	patients	not	clas-
sified	correctly,	we	made	a	broad	screening	(Table	1).	The	acquired	
list was merged with the patient list from the Norwegian registry of 
hereditary and congenital neuromuscular disorders and with the list 
obtained from the registry at the Medical genetics department at 
UNN.	We	used	data	 from	the	Norwegian	National	Registry	 to	en-
sure that all patients were alive and had their residence in Northern 
Norway. Duplicates identified by checking the Norwegian social se-
curity numbers were removed accordingly. Patients included in this 
study are children and adults with:
•	 Spinal	 muscular	 atrophy	 type	 I,	 II,	 III	 IV	 (SMAI,	 SMAII,	 SMAIII,	
SMAIV)	and	other	inherited	spinal	muscular	atrophies.
•	 Becker	 and	Duchenne	muscular	 dystrophy	 (MD),	 all	 subcatego-
ries	of	limb-girdle	muscular	dystrophy	(LGMD)	as	defined	by	the	
229th	ENMC	international	workshop	(Straub	et	al.,	2018),	facios-





• Congenital myotonia (MC) and paramyotonia congenita
• Hyper- and hypokalemic periodic paralysis and other hereditary 
periodic paralysis.
• Congenital myasthenic syndrome.
•	 All	 types	of	primary	mitochondrial	myopathies	and	other	meta-
bolic myopathies.
•	 All	 types	 of	 Charcot–Marie–Tooth	 polyneuropathies	 (CMT),	 he-
reditary neuropathy with liability to pressure palsies (HNPP) and 
other hereditary neuropathies.
A	neurologist	 (KIM)	reviewed	all	 listed	EPR	 journals.	According	
to	the	EPR,	all	included	patients	were	given	a	hereditary	neuromus-
cular	diagnosis	by	either	a	neurologist,	a	pediatrician	or	a	geneticist.	
All	 included	patients	had	 to	have	 findings	on	neurologic	 examina-
tion.	Except	for	two	patients	with	clinical	CMT	diagnosis,	all	patients	
had	abnormalities	on	either	electromyography	(EMG),	neurography,	
muscle biopsy or genetic tests that were consistent with the diag-
nosis of HNMD. Patients with other disorders that could explain the 
neurological	findings,	especially	those	with	acquired	causes	of	neu-
ropathy	 and	myopathy,	were	 excluded	 after	 thoroughly	 reviewing	
the EPR.
Diagnoses were validated independently by another neurologist 
(KAA).	Both	neurologists	had	to	concur	with	each	hereditary	neu-
romuscular diagnosis for the patient to be included. Molecular con-
firmed	diagnoses	were	verified	by	geneticists	(CJ	and	MVG).
2.2 | Statistical analysis
The	 data	 were	 analyzed	 with	 the	 Statistical	 Package	 for	 Social	
Science	26	(SPSS).	Confidence	intervals	of	95%	CI	were	calculated	
according to Wilsons score interval.
2.3 | Registration and ethics
The study was approved by the Norwegian National Committee for 
Medical	and	Health	Research	Ethics	(NR6859).	All	data	were	kept	in	
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accordance to the Declaration of Helsinki. We confirm that we have 
read the Journal's position on issues involved in ethical publication 
and affirm that this report is consistent with those guidelines. The 




9.0%	 of	 the	 total	 population	 (Figure	 1).	 According	 to	 Statistics	
Norway,	this	area	had	a	total	population	of	484,546	individuals	on	




Table 1 provides an overview of the HNMD found in our study 
according	to	the	ICD-10	code.	Mean	age	of	the	HNMD	population	
was 48.8 years (SD	 21.0)	 and	 included	 252	 (46.5%)	 females	 and	
290	 (53.5%)	 males.	 Further,	 55	 patients	 were	 children	<18 years 
old (including 43 children <16	years	old)	and	487	adults	(≥18	years	
old). The PP of children (<18	years	old)	and	adults	 (≥18	years	old)	
were	57.8/100,000	(95%	CI	44.4–75.2)	and	125.1/100,000	(95%	CI	





molecular cause was still unknown (Table 2). Table 2 provides the PP 
of the main categories of HNMD and their specific clinical diagnosis.
Of	 the	 188	 hereditary	 neuropathies,	 87	 patients	 (46.3%)	
were	 genetically	 confirmed,	 7	 (3.7%)	 patients	 have	 a	 VUS	 and	
TA B L E  1   ICD-10	codes	screened	from	January	1.	1999	–	January	1.	2020
ICD-10 Frequency (n) Percent (%)
G12.0	Infantile	spinal	muscular	atrophy,	type	I 4 0.7
G12.1	Other	inherited	spinal	muscular	atrophy 13 2.4
G12.2 Motor neuron disease 1 0.2
G12.8	Other	spinal	muscular	atrophies	and	related	syndromes 6 1.1
G12.9	Spinal	muscular	atrophy,	unspecified 5 0.9
G60.0 Hereditary motor and sensory neuropathy 149 27.5
G60.1 Refsum's disease 0 0
G60.3	Idiopathic	progressive	neuropathy 1 0.2
G60.8	Other	hereditary	and	idiopathic	neuropathies 21 3.9
G60.9 Hereditary and idiopathic neuropathy 14 2.6
G62.8	Other	specified	polyneuropathies, 0 0
G62.9	Polyneuropathy,	unspecifieda  5 0.9
G63.3 Polyneuropathy in other endocrine and metabolic diseases 0 0
G63.4 Polyneuropathy in nutritional deficiency 0 0
G63.6 Polyneuropathy in other musculoskeletal disorders 0 0
G63.8 Polyneuropathy in other diseases classified elsewhere 0 0
G70.2 Congenital and developmental myasthenia 1 0.2
G71.0 Muscular dystrophy 109 20.1
G71.1 Myotonic disorders 152 28.1
G71.2 Congenital myopathies 12 2.2
G71.3 Mitochondrial myopathy 7 1.3
G71.8	Other	primary	disorders	of	muscles 6 1.1
G71.9	Primary	disorder	of	muscle,	unspecified 17 3.1




G73.6 Myopathy in metabolic diseases 1 0.2
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for	 94	 (50.0%)	 the	 molecular	 cause	 of	 disease	 is	 still	 unknown.	
The	50	CMT	patients	with	 an	 identified	 genetic	 cause	 included:	
19	 (38.0%)	 with	 CMT1A,	 4	 (8.0%)	 with	 CMT1B,	 7	 (14.0%)	 with	
CMT1X,	7	 (14.0%)	with	CMT2A,	3	 (6.0%)	with	CMT2C,	1	 (2.0%)	
with	CMT2O,	 1	 (2.0%)	with	CMT2I/J	 and	 8	 (16.0%)	with	CMT4.	
One	 (0.7%)	 patient	 had	 a	 CMT	 diagnosis	 with	 central	 nervous	
system	 involvement	 (HMSN	V).	The	7	patients	with	a	VUS	were	
1	 CMT1,	 1	 CMT1X,	 1	 intermediary	 CMT	 and	 4	 CMT2.	 In	 the	
genetically	 undetermined	 CMT	 patients,	 22/95	 (23.2%)	 under-
went a Next-Generation sequencing panel analysis (383 genes 
listed at https://www.genet ikkpo rtalen.no/?act=genpa	n&katID	
=19&GpanI	D=21#popup108),	 27/95	 (28.4%)	 underwent	 multi	
CMT-gene	 sequencing,	 2/95	 (2.1%)	 underwent	 single	 CMT-gene	
sequencing	and	in	44/95	(46.3%)	no	genetic	CMT-testing	had	been	
ordered. The three patients with neuralgic amyotrophy that were 
not	genetically	 confirmed,	had	a	positive	 family	history,	 findings	
on	neurologic	examination,	EMG	and	neurography.
The	 three	patients	with	 unclassified	 SMA	have	not	 been	 ge-
netically tested (Table 2). Two sisters in this category (Table 2) 
were	classified	as	SMA	type	III	by	patient	history,	neurologic	ex-
amination,	 EMG	 and	muscle	 biopsy.	 The	 third	 unclassified	 SMA	








ited an expansion in the androgen receptor (AR) gene from each 
of their parents.
Hereditary myopathies including muscular channelopathies had 
a	PP	of	67.7/100,000	 (95%	CI	60.8–75.4).	We	 found	nine	patients	













Fifty-five	 patients	 with	 MC	 were	 registered,	 45	 were	 living	
in	 the	 northernmost	 county	 Finnmark-Troms.	 Accordingly,	 the	
prevalence	of	MC	 in	Finnmark-Troms	was	18.5/100,000	 (CI	95%	
13.8–24.7).
F I G U R E  1   Northern Norway in red 
color with the two Departments of 
Neurology in Northern Norway. The 
departments are located at 69°N in 
Tromsø	city,	and	at	67°N	in	Bodø	city
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TA B L E  2  Frequency,	prevalence	per	100,000	persons,	and	share	of	genetically	verified	patients	with	hereditary	neuromuscular	disorders	
in Northern Norway as of January 1. 2020
Frequency, n (%) Prevalence (95% CI)
Genetically 
confirmed, n (%)
(N = 542) 111.9 (102.8–121.7) 378 (69.7)
Neuropathies,	n	(%) 188 (34.7) 38.8	(33.6–44.8) 87 (46.3)
Charcot–Marie–Tooth	(CMT) 145	(26.8) 29.9	(25.4–35.2) 50	(34.5)
CMT1 39 (7.2) 8.0	(5.9–11.0) 23	(59.0)
CMT1X 9 (1.7) 1.9	(1.0–3.5) 7 (77.8)
CMT2 81	(15.0) 16.7	(13.5–20.8) 12 (14.8)
Intermediate 3 (0.6) 0.6	(0.2–1.8) 0 (0)
CMT4 8	(1.5) 1.7	(0.8–3.3) 8 (100)
HMSN	V 1 (0.2) 0.21	(0.04–1.17) 0 (0)
CMT unclassified 4 (0.7) 0.8	(0.3–2.1) 0 (0)
HNPP 40 (7.4) 8.3	(6.1–11.2) 37	(92.5)
Neuralgic amyotrophy 3 (0.6) 0.6	(0.2–1.8) 0 (0)
Spinal	Muscular	atrophy	(SMA) 18 (3.3) 3.7	(2.4–5.9) 12 (66.7)
SMA	type	I 1 (0.2) 0.21	(0.04–1.17) 1 (100)
SMA	type	II 1 (0.2) 0.21	(0.04–1.17) 1 (100)
SMA	type	III 8	(1.5) 0.8	(0.3–2.1) 8 (100.0)
SMA	type	IV 1 (0.2) 0.21	(0.04–1.17) 1 (100)
SMARD1 1 (0.2) 0.21	(0.04–1.17) 1 (100)
Non-5q	SMA 3 (0.6) 0.6	(0.2–1.8) 0 (0)
SMA	unclassified 3 (0.6) 0.6	(0.2–1.8) 0 (0)
Kennedy disease
Malesa  6 (1.1) 2.4	(1.1–5.3) 6 (100)
Femalesa  2 (0.4) 0.8	(0.2–3.1) 2 (100)
Myopathies (except channelopathies) 253	(46.7) 52.2	(46.2–59.1) 204 (80.6)
Duchenne muscular dystrophy (MD)a  18 (3.3) 7.3	(4.6–11.5) 15	(83.3)
Symptomatic Duchenne carriera  2 (0.4) 0.8	(0.2–0.3.1) 2 (100)
Becker	MDa  4 (0.7) 1.6	(0.6–4.2) 4 (100)
Facioscapulohumeral MD 18 (3.3) 3.7	(2.4–5.9) 13 (72.2)
Myotonic dystrophy type-1 65	(12.0) 13.4	(10.5–17.1) 61 (93.9)
Myotonic dystrophy type-2 33	(5.9) 6.8	(4.8–9.6) 33 (100)
Limb-Girdle	muscular	dystrophy	(LGMD) 62 (11.4) 12.8	(10.0–16.4) 46 (74.2)
LGMD	R1calpain3-related 4 (0.7) 0.8	(0.3–2.1) 4 (100)
LGMD	R9	FKRP-related 28	(5.2) 5.8	(4.0–8.4) 28 (100)
LGMD	R10	titin-related 1 (0.2) 0.21	(0.04–1.17) 1 (100)
LGMD	R12	anoctamin5-related 6 (1.1) 1.2	(0.6–2.7) 6 (100)
LGMD	R22	collagen	6-related 6 (1.1) 1.2	(0.6–2.7) 1 (16.7)
LGMD	D4	calpain3-related 5	(0.9) 1.0	(0.4–2.4) 5	(100)
LGMD	unclassified 11 (2.0) 2.3	(1.3–4.1) 0 (0)
Oculopharyngeal	MD 9 (1.7) 1.9	(1.0–3.5) 9 (100)
Myofibrillar MD 4 (0.7) 0.8	(0.3–2.1) 1	(25.0)
Emery-Dreifuss MD 2 (0.4) 0.4	(0.1–1.5) 2 (100)
Congenital MD 6 (1.1) 1.2	(0.6–2.7) 2 (33.3)
POMT1	MD 1 (0.2) 0.21	(0.04–1.17) 1 (100)
(Continues)
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4  | DISCUSSION
By	screening	and	 reviewing	EPRs	of	patients	 in	Northern	Norway	





2020 identified few population-based studies that estimated the 
total	 HNMD	 prevalence	 in	 all	 age	 groups	 (Hughes	 et	 al.,	 1996).	
Frequency, n (%) Prevalence (95% CI)
Genetically 
confirmed, n (%)
(N = 542) 111.9 (102.8–121.7) 378 (69.7)
LAMA2	MD 2 (0.4) 0.4	(0.1–1.5) 1	(50)
Unclassified 3 (0.6) 0.6	(0.2–1.8) 0 (0)
Unclassified	MD 2 (0.4) 0.4	(0.1–1.5) 0 (0)
Congenital myopathy 3 (0.6) 0.6	(0.2–1.8) 1 (33.3)
Nemalin myopathy 2 (0.4) 0.4	(0.1–1.5) 1	(50)
Multiminicore myopathy 1 (0.2) 0.21	(0.04–1.17) 0 (0)
Rippling muscle disease 1 (0.2) 0.21	(0.04–1.17) 1 (100)
Metabolic myopathiesb  15	(2.8) 3.1	(1.9–5.1) 10 (66.7)
Mitochondrial myopathies 10 (1.9) 2.1	(1.1–3.8) 6 (60.0)
CPO 2 (0.4) 0.4	(0.1–1.5) 1	(50)
MLASA	myopathy 2 (0.4) 0.4	(0.1–1.5) 1	(50)
MERRF 1 (0.2) 0.21	(0.04–1.17) 1 (100)
POLG	myopathy 1 (0.2) 0.21	(0.04–1.17) 1 (100)
Kearn–Sayre	syndrome 1 (0.2) 0.21	(0.04–1.17) 1 (100)
PDHD 1 (0.2) 0.21	(0.04–1.17) 1 (100)
Unclassified 2 (0.4) 0.4	(0.1–1.5) 0 (0)
Glycogen storage disorders 3 (0.6) 0.6	(0.2–1.8) 3 (100)
McArdle	disease 3 (0.6) 0.6	(0.2–1.8) 3 (100)
Lipid	storage	disorders 2 (0.4) 0.4	(0.1–1.5) 1	(50)
MADD 1 (0.2) 0.21	(0.04–1.17) 0 (0)
CPT type-2 1 (0.2) 0.21	(0.04–1.17) 1 (100)
Distal myopathies 9 (1.7) 1.9	(1.0–3.5) 5	(55.5)
MYH-7	related	myopathy 6 (1.1) 1.2	(0.6–2.7) 3	(50.0)
Welander distal myopathy 1 (0.2) 0.21	(0.04–1.17) 1 (100.0)
GNE myopathy 1 (0.2) 0.21	(0.04–1.17) 1 (100.0)
Distal myopathy unclassified 1 (0.2) 0.21	(0.04–1.17) 0 (0)
Channelopathies 75	(13.9) 15.5	(12.3–19.4) 67 (89.3)
Myotonia Congenita (MC) 55	(10.2) 11.4	(8.7–14.8) 48 (87.3)
Thomsen dominant MC 11 (2.0) 2.3	(1.3–4.1) 10 (90.9)
Becker	recessive	MC 38 (7.0) 7.8	(5.7–10.8) 38 (100)
Unclassified	MC 6 (1.1) 1.2	(0.6–2.7) 0 (0)
Paramyotonia Congenita 7 (1.3) 1.4	(0.7–3.0) 7 (100)
Hypokalemic periodic paralysis 12 (2.2) 2.5	(1.4–4.3) 11 (91.7)




Duchenne carrier calculated from the share of women in the population. 
bCPO,	chronic	progressive	external	opthalmoplegia;	MLASA,	lactic	acidosis	and	sideroblastic	anemia;	MERRF,	myoclonic	epilepsy	with	ragged-red	
fibers;	PDHD,	Pyruvate	dehydrogenase	deficiency;	MADD,	myoadenylate	deaminase	deficiency	and	CPT,	Carnitine	palmitoyl	transferase	deficiency.	
TA B L E  2   (Continued)
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The prevalence found in the current study is more than three 
times	 higher	 than	 proposed	 in	 1991,	 in	 a	 historical	 epidemio-
logical study that combined populations from different parts of 
the	 world	 (33/100,000)	 (Emery,	 1991).	 Although	 this	 was	 con-
sidered	 a	 conservative	 estimate,	 a	 similar	 prevalence	was	 found	




bine the prevalence numbers from their adult population with a 
prevalence study on children (<16year)	in	West	Sweden,	the	total	
HNMD	 prevalence	 would	 probably	 exceed	 100/100,000	 (Darin	
&	 Tulinius,	 2000;	 Lefter	 et	 al.,	 2017).	 In	 a	 study	 from	Northern	
England	 a	 prevalence	 of	 37/100,000	 for	 hereditary	 myopathies	
and	 40/100,000	 for	 hereditary	 neuropathies	 were	 established	
(Norwood	 et	 al.,	 2009).	 The	 authors	 state	 that	 by	 adding	 prev-
alence numbers from diagnoses they excluded (mitochondrial 
and	metabolic	myopathies,	McArdle	disease,	 late	Pompe	disease	
and	 MC),	 the	 prevalence	 of	 hereditary	 myopathies	 would	 be	
50/100,000	 (Norwood	 et	 al.,	 2009).	 Likewise,	 if	 all	 the	 HNMD	
would	be	considered,	the	prevalence	 in	Northern	England	would	
be	close	to	100/100,000	(Norwood	et	al.,	2009).	In	line	with	the	
previous	 reasoning,	 combining	 results	 from	 two	 recent	 studies	
from Spain would hypothetically give a total HNMD prevalence of 
102/100,000	(Lousa	et	al.,	2019;	Pagola-Lorz	et	al.,	2019).
Although	speculative,	 these	 recent	 total	estimates	 from	differ-
ent European populations are lower than the total prevalence of 
HNMD	in	our	study,	but	they	correspond	well	with	our	prevalence	
of	52.2/100,000	 for	hereditary	myopathies	 and	38.8/100,000	 for	
hereditary neuropathies. The higher total prevalence in our study 
can	partly	be	explained	by	the	high	prevalence	of	MC	and	LGMD-R9	
FKRP-related	 disease.	On	 the	 other	 hand,	 two	 recently	 published	
studies from New Zealand found a total HNMD prevalence of 
49/100,000,	 suggesting	 ethnic	 differences	 (Theadom,	 Rodrigues,	
et	al.,	2019;	Theadom,	Roxburgh,	et	al.,	2019).
A	study	from	South	Norway	by	Rasmussen	and	colleagues	found	
that the minimum prevalence of children with HNMD <18 years 
of	age	was	36/100,000,	which	contrasts	 the	57/100,000	found	 in	
West Sweden in children <16	 years	 old	 (Darin	 &	 Tulinius,	 2000;	
Rasmussen	et	al.,	2012).	However,	 the	Swedish	 study	used	similar	
methods as the ones applied in the current study and found results 
within	the	range	of	the	currently	presented	results	 (51.3/100,000)	
(Darin	&	Tulinius,	2000).	Noticing	the	similarities,	we	trust	that	the	
total prevalence of HNMD in children (<18 years) in Scandinavia is 
within	the	CI	of	our	estimate	(44.4–75.2/100,000).
In	 the	 current	 study,	 the	 prevalence	 of	 CMT	 neuropathies	 is	
in the upper range of that previously reported in Europe (Foley 
et	 al.,	 2012;	 Lousa	 et	 al.,	 2019),	 but	 historically	 even	 higher	 val-
ues	 have	 been	 found	 in	 two	 Norwegian	 populations	 (Braathen	
et	al.,	2011;	Skre,	1974).	In	1968,	Skre	found	275	patients	with	CMT	
in	West	 Norway,	 giving	 a	 prevalence	 of	 42.3/100,000.	 However,	






Norway,	equal	 to	 the	prevalence	of	34/100,000	 (1817/5,328,000)	
for	 all	 of	 Norway	 (unpublished	 data).	 A	 similar	 prevalence	 was	




Surprisingly,	 in	 our	 study	 CMT2	was	 the	 most	 common	 CMT,	
encompassing	 55.9%	 of	 the	 total.	 Among	 CMT	 diagnosis,	 CMT1	
predominates	in	most	publications.	However,	an	earlier	Norwegian	
study found an equal distribution between CMT1 and CMT2 diag-
noses,	whereas	a	similar	higher	preponderance	of	CMT2	has	been	
found	 in	Japan	 (Braathen	et	al.,	2011;	Kurihara	et	al.,	2002).	Since	




tients with a CMT diagnosis included in our study were genetically 





lated	 disease,	 but	 other	 subcategories	 may	 dominate	 in	 different	




related	 disease.	 Similarly,	 in	 the	Danish	 population	 a	 high	 propor-
tion	(38%)	of	LGMD	R9	FKRP-related	disease	was	reported	(Sveen	
et	al.,	2006).	The	prevalence	of	6/100,000	in	our	study	is	three	times	
higher than stated in an early report in the Norwegian population 
(Stensland	et	al.,	2011),	and	it	is	much	higher	than	recently	reported	
in	the	south	west	of	Norway	(0.8/100,000)	(Husebye	et	al.,	2020).	
The	 prevalence	 of	 LGMD	R9	 FKRP-related	 disease	 in	 the	 current	





disease	 in	 the	 unclassified	 LGMD	 and	 unclassified	 muscular	 dys-
trophy	patients	(Table	2),	this	disorder	seems	to	be	less	frequent	in	
Norway	(Husebye	et	al.,	2020).	As	compared	to	south	west	Norway,	
another less frequent metabolic myopathy in our population was 
McArdle	 disease	 (Husebye	 et	 al.,	 2020).	 Nevertheless,	 our	 preva-
lence	finding	of	McArdle	is	comparable	to	a	study	of	the	Irish	popu-
lation	(Lefter	et	al.,	2017).
Most	 studies	 report	 a	 prevalence	 of	 MC	 below	 0.5/100,000	
in	 the	 Caucasian	 populations	 (Emery,	 1991),	 and	 it	 is	 extremely	
rare	 in	other	ethnicities	 (Jou	et	al.,	2004).	A	recent	hospital-based	
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population study in south west Norway found a higher MC prev-
alence	 of	 2.8/100,000	 (Husebye	 et	 al.,	 2020).	 However,	 one	 of	





county) in this study is probably due to access to better screening 
methods in addition to a more thorough review of different medical 
and genetic EPR. These findings are the highest identified preva-
lence of MC worldwide. The higher prevalence of MC found in both 
Norway where it increases at higher latitude and northern Finland is 
probably due to founder mutations.
Hypokalemic periodic paralysis is an extremely rare disorder. 
Two European epidemiological studies found a prevalence of less 
than	 0.5/100,000	 (Horga	 et	 al.,	 2013;	 Lefter	 et	 al.,	 2017).	 The	
higher	 occurrence	 in	 our	 population	 (2.5/100,000)	 might	 be	 be-
cause	the	disease	was	identified	in	a	few,	but	large	families.	We	did	




these channelopathies could be less frequent in Norway (Husebye 
et	al.,	2020).	However,	another	logic	explanation	is	the	cohort	size	
of our study together with the rarity of these disorders. The prev-
alence	 of	 the	 other	 reported	HNMD	 in	 our	 population	 (Table	 2),	
were consistent with previously published studies.
Hereditary neuromuscular disorders are rare and accordingly 
the current study has some weaknesses. The PP can be influenced 
significantly	 if	a	few	patients	have	not	been	registered,	or	 if	an	in-
correct	 diagnosis	 is	 set.	 To	 avoid	 this,	we	 investigated	 thoroughly	
both	multiple	EPR	and	registries	covering	21	years	back	in	time,	and	
involved two neurologists and two geneticists to secure correct di-
agnostic procedures. Except from two patients with CMT all diagno-
ses that were not genetically verified had findings on neurological 
examination and either EMG/neurography or muscle biopsy that 
corresponded	with	an	HNMD.	Nevertheless,	diagnoses	that	are	not	
genetically confirmed represent a possible weakness in prevalence 




However,	 a	 strength	 of	 the	 current	 study	 is	 that	 Northern	
Norway is sparsely populated and travel distances to hospitals 
outside the area is extensive. The only neurologic departments are 
located	in	Tromsø	and	Bodø	(Figure	1).	Due	to	the	huge	distances	
to	other	neurologic	departments	and	hospitals,	it	is	less	likely	that	
patients with HNMD have regularly been followed up in hospi-
tals	outside	this	area.	Those	few,	who	travel	to	other	areas,	would	
most likely have been scheduled for local follow-up management. 
By	using	different	sources	and	including	all	patients	seeking	spe-
cialist	 care,	 we	 do	 believe	 to	 have	 obtained	 robust	 prevalence	
numbers for HNMD.
Another	advantage	of	the	current	study	is	that	Norwegian	health	
insurance is equal for the complete population and everybody has the 
same	rights	 to	 treatment.	However,	some	patients,	especially	 those	
with	milder	disabilities,	might	not	find	it	necessary	to	seek	healthcare	
services	(e.g.,	some	MC,	DM1,	CMT	and	HNPP).	The	fact	that	almost	




nic variations of HNMD do exist. Due to the phenotypic variability 
and	 the	 rarity	 of	 these	 disorders,	 a	 future	 comprehensive	 popula-
tion-based	epidemiological	study	based	on	EPR,	the	Norwegian	reg-
istry of hereditary and congenital neuromuscular disorders as well as 
patient	organizations	at	a	national	level	is	warranted.
5  | CONCLUSION
The total HNMD prevalence in this study was higher than the preva-
lence of HNMD in hypothetical estimates made from studies across 
Europe.	Among	the	subcategories,	we	found	high	prevalence	of	MC	
and	LGMD	R9-FKRP-related	disease,	and	contradicted	the	previous	
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